CL2017001566A1 - Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. - Google Patents

Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.

Info

Publication number
CL2017001566A1
CL2017001566A1 CL2017001566A CL2017001566A CL2017001566A1 CL 2017001566 A1 CL2017001566 A1 CL 2017001566A1 CL 2017001566 A CL2017001566 A CL 2017001566A CL 2017001566 A CL2017001566 A CL 2017001566A CL 2017001566 A1 CL2017001566 A1 CL 2017001566A1
Authority
CL
Chile
Prior art keywords
treatment
azabicycloothane
liver
derivatives
gastrointestinal diseases
Prior art date
Application number
CL2017001566A
Other languages
English (en)
Spanish (es)
Inventor
Lloyd B Klickstein
Michael Badman
Bryan Laffitte
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001566(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001566A1 publication Critical patent/CL2017001566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CL2017001566A 2014-12-18 2017-06-16 Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. CL2017001566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093586P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
CL2017001566A1 true CL2017001566A1 (es) 2018-03-23

Family

ID=54979887

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001566A CL2017001566A1 (es) 2014-12-18 2017-06-16 Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.

Country Status (17)

Country Link
US (2) US20170368038A1 (cg-RX-API-DMAC7.html)
EP (1) EP3233083A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017537960A (cg-RX-API-DMAC7.html)
KR (1) KR20170095965A (cg-RX-API-DMAC7.html)
CN (1) CN107106555A (cg-RX-API-DMAC7.html)
AU (1) AU2015365481B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017011972A2 (cg-RX-API-DMAC7.html)
CA (1) CA2970866A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001566A1 (cg-RX-API-DMAC7.html)
IL (1) IL252596A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017008057A (cg-RX-API-DMAC7.html)
PH (1) PH12017501046A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017125365A (cg-RX-API-DMAC7.html)
SG (1) SG11201704340VA (cg-RX-API-DMAC7.html)
TN (1) TN2017000243A1 (cg-RX-API-DMAC7.html)
TW (1) TW201628615A (cg-RX-API-DMAC7.html)
WO (1) WO2016097933A1 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PT3277286T (pt) 2015-03-31 2021-07-01 Enanta Pharm Inc Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
JP7093341B2 (ja) * 2016-08-23 2022-06-29 アルデリックス， インコーポレイテッド 代謝異常状態及び代謝障害を治療するためのホルモン受容体調節薬
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
RU2019113066A (ru) 2016-10-04 2020-11-09 Энанта Фармасьютикалс, Инк. Аналоги изоксазола как агонисты fxr и способы их применения
MX2019003889A (es) * 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
PT4122464T (pt) 2017-03-28 2024-06-27 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças do fígado
NZ758117A (en) 2017-04-12 2022-01-28 Il Dong Pharma Isoxazole derivatives as nuclear receptor agonists and uses thereof
MX2020000268A (es) * 2017-07-06 2020-07-22 Xuanzhu Biopharmaceutical Co Ltd Agonista de fxr.
JP7271513B2 (ja) * 2017-09-14 2023-05-11 アルデリックス， インコーポレイテッド 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬
AU2018360575A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
WO2019089667A1 (en) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
EP3704114B1 (en) 2017-11-01 2022-11-23 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
ES2944657T3 (es) 2017-11-01 2023-06-23 Bristol Myers Squibb Co Compuestos de alqueno como moduladores del receptor farnesoide X
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
EP3730491B1 (en) 2017-12-22 2022-07-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Isoxazole derivative, preparation method therefor, and use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2019183004A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN110357875B (zh) * 2018-04-10 2022-06-21 浙江海正药业股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途
CN110357876B (zh) * 2018-04-10 2022-06-28 浙江海正药业股份有限公司 氮杂双环辛烷类衍生物及其制备方法和用途
CN112334467B (zh) * 2018-06-26 2023-06-20 轩竹生物科技股份有限公司 Fxr受体激动剂
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
SG11202107434PA (en) 2019-01-15 2021-08-30 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA3128416A1 (en) * 2019-01-31 2020-08-06 The National Institutes of Pharmaceutical R&D Co., Ltd. Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof
EP3924337A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
JP7550777B2 (ja) 2019-02-15 2024-09-13 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020221371A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
CN111825701B (zh) * 2019-04-19 2023-12-08 正大天晴药业集团股份有限公司 含苯并噻唑的三环类fxr调节剂化合物
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
WO2021104021A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
CN114728954B (zh) * 2019-11-29 2023-10-17 广东东阳光药业股份有限公司 Tropifexor的新晶型及其制备方法
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
EP4161925A4 (en) * 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
US20230226143A1 (en) * 2020-06-30 2023-07-20 Ocvirk, Soren Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
CN113292555B (zh) * 2021-04-28 2022-03-18 武汉纽瑞斯医药科技有限公司 一种Tropifexor的制备方法
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN116987062A (zh) * 2023-08-03 2023-11-03 中国热带农业科学院分析测试中心 一种氨基酸键联槟榔碱衍生物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
US20130261108A1 (en) * 2010-12-20 2013-10-03 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds

Also Published As

Publication number Publication date
BR112017011972A2 (pt) 2017-12-26
TN2017000243A1 (en) 2018-10-19
WO2016097933A1 (en) 2016-06-23
AU2015365481B2 (en) 2018-08-09
US20190083473A1 (en) 2019-03-21
RU2017125365A3 (cg-RX-API-DMAC7.html) 2019-07-17
IL252596A0 (en) 2017-07-31
JP2017537960A (ja) 2017-12-21
US20170368038A1 (en) 2017-12-28
RU2017125365A (ru) 2019-01-21
TW201628615A (zh) 2016-08-16
CA2970866A1 (en) 2016-06-23
KR20170095965A (ko) 2017-08-23
EP3233083A1 (en) 2017-10-25
CN107106555A (zh) 2017-08-29
AU2015365481A1 (en) 2017-06-22
MX2017008057A (es) 2017-09-28
SG11201704340VA (en) 2017-07-28
PH12017501046A1 (en) 2017-11-27

Similar Documents

Publication Publication Date Title
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2021003311A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
CL2016001895A1 (es) Compuestos
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2022013114A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
DOP2017000178A (es) Inhibidores selectivos de bace1
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2017002705A (es) Sondas para la proyección de imagen de la proteína huntingtina.
MX386798B (es) Sondas para la proyección de imagen de la proteína huntingtina.
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы